by Kalpana Parvathaneni, and David W. Scott

Slides:

Advertisements

Similar presentations

Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man Immunity

Advertisements

Volume 17, Issue 9, Pages (September 2009)

Notch signaling induces cytoplasmic CD3ϵ expression in human differentiating NK cells by Magda De Smedt, Tom Taghon, Inge Van de Walle, Greet De Smet,

Volume 25, Issue 10, Pages (October 2017)

Volume 28, Issue 2, Pages (February 2008)

by Rafijul Bari, Teresa Bell, Wai-Hang Leung, Queenie P

Identification of CD3+CD4−CD8− T Cells as Potential Regulatory Cells in an Experimental Murine Model of Graft-Versus-Host Skin Disease (GVHD) Fumi Miyagawa,

Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide by Yoshinori Nagai, Rintaro Shimazu, Hirotaka.

Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer by Ou Cao, Eric Dobrzynski,

Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.

Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion by Yenan T. Bryceson, Michael E. March, Hans-Gustaf.

Volume 15, Issue 2, Pages (February 2007)

Malaria-specific transgenic CD4+ T cells protect immunodeficient mice from lethal infection and demonstrate requirement for a protective threshold of antibody.

by Norman Nausch, Ioanna E

Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells by Wuding Zhou, Hetal Patel, Ke Li, Qi Peng, Marie-Bernadette.

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia by Donya Moradi Manesh, Jad El-Hoss, Kathryn.

Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists by Christopher T.

Volume 17, Issue 8, Pages (August 2009)

by Éric Aubin, Réal Lemieux, and Renée Bazin

by Takahiro Kamiya, Desmond Wong, Yi Tian Png, and Dario Campana

Volume 40, Issue 2, Pages (February 2014)

Volume 130, Issue 2, Pages (February 2006)

Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation by Eric Boilard, Guillaume Paré, Matthieu Rousseau, Nathalie.

Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity by Mikael Maksimow, Mari.

TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow by Shoichiro Tsuji, Catarina Cortesão,

by Cunren Liu, Shaohua Yu, John Kappes, Jianhua Wang, William E

by Bindu Varghese, Adam Widman, James Do, Behnaz Taidi, Debra K

Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15 by Lazar.

Volume 18, Issue 5, Pages (May 2003)

Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival by Matthew Gumbleton, Raki Sudan,

Volume 17, Issue 8, Pages (August 2009)

Volume 21, Issue 1, Pages (October 2017)

Volume 28, Issue 4, Pages (October 2015)

Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets by Anne Zufferey, Edwin R. Speck, Kellie R.

PD-1 blockade enhances elotuzumab efficacy in mouse tumor models

Volume 26, Issue 4, Pages (April 2018)

Volume 17, Issue 8, Pages (August 2009)

by Kamira Maharaj, John J

Volume 24, Issue 9, Pages (September 2016)

Volume 16, Issue 11, Pages (September 2016)

by Sondra Downey-Kopyscinski, Ellen W

Role of B cells in TH cell responses in a mouse model of asthma

by Juan Chen, Jocelyn A. Schroeder, Xiaofeng Luo, and Qizhen Shi

by Seema R. Patel, Ashley Bennett, Kathryn Girard-Pierce, Cheryl L

Volume 20, Issue 13, Pages (September 2017)

Volume 12, Issue 5, Pages (November 2005)

Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein by Rupali Das, Peng Guan, Susan J. Wiener,

Volume 23, Issue 7, Pages (May 2018)

by Derek Hoi-Hang Ho, and Roger Hoi-Fung Wong

Volume 22, Issue 1, Pages (January 2014)

Volume 24, Issue 1, Pages (January 2016)

Molecular Therapy - Oncolytics

Human hematopoietic stem cell maintenance and myeloid cell development in next-generation humanized mouse models by Trisha R. Sippel, Stefan Radtke, Tayla.

In Vivo Expansion of Regulatory T cells With IL-2/IL-2 mAb Complexes Prevents Anti- factor VIII Immune Responses in Hemophilia A Mice Treated With Factor.

Arp2/3-mediated formation of nuclear actin networks is essential for CD4+ T cell effector functions. Arp2/3-mediated formation of nuclear actin networks.

Serial vaccination with 32Dp210-derived whole cell vaccines in non-tumor-bearing mice stimulates robust antileukemic cytolytic activity. Serial vaccination.

by Hakan Köksal, Pierre Dillard, Sarah E

Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies by Nadine Müller-Calleja, Svenja.

FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice by Simone Merlin, Rosella Famà, Ester.

TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice by Dipica Haribhai, Xiaofeng.

Volume 17, Issue 5, Pages (May 2009)

Volume 23, Issue 1, Pages (January 2015)

Volume 20, Issue 3, Pages (March 2012)

Volume 25, Issue 4, Pages (April 2017)

The Coinhibitory Receptor CTLA-4 Controls B Cell Responses by Modulating T Follicular Helper, T Follicular Regulatory, and T Regulatory Cells Peter T.

by Martin Felices, Behiye Kodal, Peter Hinderlie, Michael F

Local Inhibition of Complement Improves Mesenchymal Stem Cell Viability and Function After Administration Yan Li, John Fung, Feng Lin Molecular Therapy

Loss of Transgene following ex vivo Gene Transfer is Associated with a Dominant Th2 Response: Implications for Cutaneous Gene Therapy Zhenmei Lu, Soosan.

Volume 20, Issue 6, Pages (June 2012)

Volume 25, Issue 4, Pages (April 2017)

Presentation transcript:

by Kalpana Parvathaneni, and David W. Scott Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo by Kalpana Parvathaneni, and David W. Scott BloodAdv Volume 2(18):2332-2340 September 25, 2018 ©2018 by American Society of Hematology

Kalpana Parvathaneni, and David W. Scott Blood Adv 2018;2:2332-2340 ©2018 by American Society of Hematology

Design and properties of BARs Design and properties of BARs. (A) Schematic representation of the BAR constructs containing FVIII-A2 or FVIII-C2 or OVA. (B) Representation of BAR-expressing T cells engaging with the antigen-specific B cell through their surface BCR. (C) Green fluorescent protein (GFP) expression levels in transduced mouse CD8 T cells at day 7. Design and properties of BARs. (A) Schematic representation of the BAR constructs containing FVIII-A2 or FVIII-C2 or OVA. (B) Representation of BAR-expressing T cells engaging with the antigen-specific B cell through their surface BCR. (C) Green fluorescent protein (GFP) expression levels in transduced mouse CD8 T cells at day 7. Inlet picture shows the fluorescent imaging of cells in culture 72 hours after transduction. (D) Single-cell imaging analysis and expression of CD8 on the surface and intracellular localization of GFP, interferon-γ (IFN-γ), perforin, and granzyme B (Gzym B) 6 hours after stimulation with anti-A2 or anti-C2 antibodies in the presence of protein transport inhibitor. Far right panel indicates the overlay of GFP, granzyme B, and perforin channels. (E) Flow cytometry analysis of C2-BAR and OVA-BAR CD8 T cells after stimulation with respective antibodies and increase in cytolytic granule proteins, such as granzyme B and perforin. Hu, human; IRES, internal ribosome entry site; PE, phycoerythrin. Kalpana Parvathaneni, and David W. Scott Blood Adv 2018;2:2332-2340 ©2018 by American Society of Hematology

Specific cytotoxicity of BAR CD8s in vitro and in vivo. Specific cytotoxicity of BAR CD8s in vitro and in vivo. (A-B) Quantification of FVIII-specific spots formed by 3G6 and 413 hybridomas after coculture with BAR effector CD8 T cells (P = .0157). (C) Dose-dependent killing of target cells (BO2C11) by C2-BAR–expressing human CD8 T cells. (D) Loss of FVIII-specific IgG antibody secretion by BO2C11 cells at increasing effector:target (E:T) ratio of C2-BAR human CD8 T cells compared with controls (P < .05). (E) Schematic diagram of adoptive cell transfer into NSG mice and sample collection. (F) Kaplan-Meier survival analysis of NSG mice injected with BO2C11 hybridoma cells (n = 5). Log-rank (Mantel-Cox) test P = .0104. CPM, counts per minute; hCD8+, human CD8+; SD, standard deviation; SEM, standard error of the mean. Kalpana Parvathaneni, and David W. Scott Blood Adv 2018;2:2332-2340 ©2018 by American Society of Hematology

Effect of A2/C2-BAR CD8 T cells on naïve B cells. Effect of A2/C2-BAR CD8 T cells on naïve B cells. (A) Significant loss of IgM+ FVIII-specific spot formation with LPS stimulation of naïve B cells in A2/C2-BAR–treated group compared with control OVA-BAR or no T-cell groups (P = .0209). (B) Dose-dependent effect of A2-BAR, C2-BAR, or A2/C2-BAR CD8 T cells on the LPS-stimulated naïve B cells to form IgM+ FVIII-specific spots compared with the OVA-BAR group (P = .001). (C) TNP-specific IgM (top) or OVA-specific IgM (bottom) secretion by the LPS-stimulated naïve B cells in the presence of either OVA- or A2/C2-BAR–expressing T cells. Kalpana Parvathaneni, and David W. Scott Blood Adv 2018;2:2332-2340 ©2018 by American Society of Hematology

Effect of BAR CD8 T cells on the antibody response to FVIII in vivo. Effect of BAR CD8 T cells on the antibody response to FVIII in vivo. (A) Schematic diagram of immunization and sample collection with n = 5 per group of A2/C2-BAR– or OVA-BAR–injected animals. (B) Anti-FVIII concentrations in serum at different time points after injecting BAR T cells and FVIII immunization. P < .05 at weeks 4, 5, 9, and 10; P < .01 at week 12. (C) FVIII-specific IgG spot formation by naïve B cells isolated from mouse injected with A2/C2-BAR or phosphate-buffered saline upon coculture with FVIII (1 μg/mL) for 5 days (P = .0087). Bars indicate standard error. IFA, incomplete Freund’s adjuvant; rFVIII, recombinant FVIII; s.c., subcutaneously. Kalpana Parvathaneni, and David W. Scott Blood Adv 2018;2:2332-2340 ©2018 by American Society of Hematology